PCR68 Estimation of Minimal Clinically Important Difference (MCID) for the Tardive Dyskinesia Impact Scale (TDIS), a Tardive Dyskinesia-Specific Patient-Reported Outcome
Robert Farber(Neurocrine Biosciences (United States)), Christoph U. Correll(German Centre for Cardiovascular Research), Michael Bron(Neurocrine Biosciences (United States)), Susan D. Mathias(Health Outcomes Solutions (United States)), M. Mercedes Pérez-Rodríguez(Icahn School of Medicine at Mount Sinai), Eduardo Dunayevich(Neurocrine Biosciences (United States)), Donald E. Stull(IQVIA (United States)), H. Zhang(Neurocrine Biosciences (United States))
Cited by 0
Related Papers
Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies
|Molecular Psychiatry|2021|3.6k
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
|World Psychiatry|2011|2.5k
How mental health care should change as a consequence of the COVID-19 pandemic
|The Lancet Psychiatry|2020|1.9k
Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls
|World Psychiatry|2017|1.7k
The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness
|The Lancet Psychiatry|2019|1.5k